IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
40.11
-1.66 (-3.97%)
Aug 28, 2026, 4:00 PM EDT - Market closed
IDEAYA Biosciences Employees
IDEAYA Biosciences had 145 employees as of December 31, 2025. The number of employees increased by 14 or 10.69% compared to the previous year.
Employees
145
Change (1Y)
14
Growth (1Y)
10.69%
Revenue / Employee
$1,614,669
Profits / Employee
-$1,207,034
Market Cap
3.87B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 145 | 14 | 10.69% | 145 | 0 |
| Dec 31, 2024 | 131 | 7 | 5.65% | 131 | 0 |
| Dec 31, 2023 | 124 | 21 | 20.39% | 124 | 0 |
| Sep 30, 2023 | 122 | 27 | 28.42% | 122 | 0 |
| Jun 30, 2023 | 116 | 25 | 27.47% | 116 | 0 |
| Mar 31, 2023 | 107 | 20 | 22.99% | 107 | 0 |
| Dec 31, 2022 | 103 | 22 | 27.16% | 103 | 0 |
| Sep 30, 2022 | 95 | 12 | 14.46% | 95 | 0 |
| Jun 30, 2022 | 91 | 16 | 21.33% | 91 | 0 |
| Mar 31, 2022 | 87 | 18 | 26.09% | 87 | 0 |
| Dec 31, 2021 | 81 | 19 | 30.65% | 81 | 0 |
| Sep 30, 2021 | 83 | 25 | 43.10% | 83 | 0 |
| Jun 30, 2021 | 75 | 29 | 63.04% | 75 | 0 |
| Mar 31, 2021 | 69 | 26 | 60.47% | 69 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Telix Pharmaceuticals | 1,184 |
| Iovance Biotherapeutics | 975 |
| Arcus Biosciences | 601 |
| AbCellera Biologics | 562 |
| Denali Therapeutics | 507 |
| Relay Therapeutics | 202 |
| Tango Therapeutics | 137 |
IDYA News
- 2 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 11 days ago - Ideaya Biosciences enters IDE892 collaboration with Genentech - TheFly
- 11 days ago - IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer - PRNewsWire
- 23 days ago - Ideaya Biosciences price target lowered to $42 from $45 at Citizens - TheFly
- 25 days ago - Ideaya Biosciences price target raised to $60 from $58 at Wedbush - TheFly
- 25 days ago - Ideaya Biosciences price target lowered to $59 from $63 at Truist - TheFly
- 26 days ago - Ideaya Biosciences reports Q2 EPS ($1.22), consensus ($1.05) - TheFly
- 26 days ago - IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update - PRNewsWire